Question | Discussion | References | CME Credit

Case 2: Antiretroviral Regimens

You answered:

D Tenofovir-emtricitabine (Truvada) plus lopinavir-ritonavir (Kaletra)

This answer is incorrect. This combination of drugs is not considered a preferred regimen because lopinavir-ritonavir is no longer a preferred protease inhibitor, except when used in pregnant women in combination with zidovudine-lamivudine.

Choose another answer:

A Zidovudine-lamivudine (Combivir) plus efavirenz (Sustiva)
B Tenofovir-emtricitabine (Truvada) plus ritonavir (Norvir) plus darunavir (Prezista)
C Abacavir-lamivudine (Epzicom) plus raltegravir (Isentress)

[Back to Case 2 Question | Go to Correct Answer]